The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise
NCT ID: NCT05020808
Last Updated: 2022-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2021-09-14
2022-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Plant-blend Protein Isolate on Post-exercise Myofibrillar Protein Synthesis
NCT06129513
Aminoacidemia and Protein Kinetics in Response to the Ingestion of Plant-based Protein Blends
NCT05139160
Effect of a Novel Blend of Plant Protein and Additional Ingredients on Resistance Training Adaptations
NCT06908811
The Effects Potato Protein on Rates of Myofibrillar Muscle Protein Synthesis in Young Women
NCT04302038
Bioavailability of Plant Protein Amino Acids
NCT04872530
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Preliminary screening/familiarization consists of: medical history, dietary assessment and examination by a medical doctor and a qualified dietician, blood sample to be evaluated for health-related contraindications, body composition measurement by dual energy x-ray absorptiometry (DXA), isokinetic knee extensor strength tests.
Pre-trial: A metered dose of deuterium oxide (5ml/kg) will be ingested and blood and/or saliva (\~5ml) samples will be collected pre/post ingestion.
Experimental trial: Blood, saliva and bilateral m.vastus lateralis microbiopsies (\~100 mg) collected. A unilateral resistance-training session consisting of knee extensor contractions will be completed. Following exercise cessation participants will ingest 0.33 g/kg body mass of either: a nonessential amino acid formulation or a plant-protein isolate. A saliva sample and a 2nd set of bilateral m.vastus lateralis microbiopsies are collected 3 h postingestion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nonessential amino acid formulation (NEAA)
Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.
Product Number: NEAA56812
NEAA
Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Plant Protein Isolate (PPI)
Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies.
Product Number: FP2011273
PPI
Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NEAA
Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
PPI
Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Blood borne disease risk, current illness or medication that would adversely affect participation
* Known adverse reaction to venepuncture and/or biopsy
* Inability to undertake resistance exercise
* Inability to adhere to protocol guidelines
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marigot Ltd.
INDUSTRY
Enterprise Ireland
OTHER_GOV
University of Limerick
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert Davies
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip M Jakeman, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Limerick
Robert W Davies, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Limerick
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Limerick
Limerick, Munster, Ireland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020_04_07_EHS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.